Company profile
Bio-Rad Laboratories, Inc.
NYSE: BIO · Healthcare · Medical - Devices
#98 of 1,418 Healthcare companies by revenue43rd-percentile growth
EA Score
84B+FH 84DQ 96GM 53SS 96
v0.1 · 65/100 weight · provisional
↑ listing tenure, filing timeliness · ↓ growth stability, revenue growth (YoY)
Methodology →Revenue TTM
$2.6B
Rev growth YoY (TTM)
+1.9%
Net income (FY)
$759.9M
Employees
7,450
as of 2026-08-06
Market cap
$9.4B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.6B$2.6B2025
Net income$759.9M$759.9M2025
Operating income$47.2M$47.2M2025
Total assets$10.6B$10.6B2025
Liabilities$3.1B$3.1B2025
Equity$7.5B$7.5B2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY23
FY23
FY24
FY24
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Clinical Diagnostics60%
Life Science40%
By geography
UNITED STATES40%
Europe34%
Asia Pacific20%
Americas6%
The read
What is Bio-Rad Laboratories, Inc.’s revenue?
Bio-Rad Laboratories, Inc. booked $2.6B in FY2025 revenue, growing 0.7% year over year — about the middle of the pack among Healthcare companies we track, at a 29.4% net margin.
Peers · Healthcare
Fortrea Holdings Inc.50DEnvista Holdings Corp73BInsulet Corp.83B+Medpace Holdings, Inc.84B+Chemed Corporation89ATeladoc Health, Inc.69BNeighbors
Contra Costa →Key facts
CEONorman D. Schwartz
SectorHealthcare
IndustryMedical - Devices
HeadquartersHercules, CA
ExchangeNYSE: BIO
Employees7,450
IPO date1980-02-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.